<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Acinetobacter baumannii - UTI PathoDB</title>
    <link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
</head>
<body class="bg-gray-50 text-gray-900">

    <header class="bg-blue-600 text-white p-4 shadow-md">
        <h1 class="text-2xl font-bold text-center">Acinetobacter baumannii - UTI PathoDB</h1>
    </header>

    <main class="p-6 space-y-6 max-w-4xl mx-auto">

        <!-- Overview -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Overview</h2>
            <p>
                <strong>Acinetobacter baumannii</strong> is an opportunistic Gram-negative bacterium that is commonly associated with hospital-acquired infections, including urinary tract infections (UTIs). It is known for its remarkable ability to develop resistance to multiple antibiotics, making treatment difficult.
            </p>
        </section>

        <!-- Characteristics -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Characteristics</h2>
            <ul class="list-disc list-inside space-y-1">
                <li>Gram-negative coccobacillus</li>
                <li>Non-motile, oxidase-negative</li>
                <li>Highly resistant to desiccation and disinfectants</li>
                <li>Capable of forming biofilms on surfaces and medical devices</li>
            </ul>
        </section>

        <!-- Pathogenicity -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Pathogenicity</h2>
            <p>
                A. baumannii is implicated in UTIs, bloodstream infections, pneumonia, and wound infections, particularly in intensive care unit (ICU) patients. Its pathogenicity is largely due to its biofilm formation, resistance mechanisms, and survival on hospital surfaces.
            </p>
        </section>

        <!-- Clinical Significance -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Clinical Significance</h2>
            <p>
                The bacterium has become a global threat due to its multidrug resistance (MDR), including carbapenem resistance. UTIs caused by A. baumannii are difficult to treat and are often associated with catheterization and prolonged hospital stays.
            </p>
        </section>

        <!-- Treatment -->
        <section>
            <h2 class="text-xl font-semibold mb-2">Treatment</h2>
            <p>
                Treatment options include combination therapy with colistin, tigecycline, and carbapenems, but resistance to these drugs is increasing. Phage therapy and novel antibiotics are under investigation.
            </p>
        </section>

        <!-- References -->
        <section>
            <h2 class="text-xl font-semibold mb-2">References</h2>
            <ul class="list-decimal list-inside space-y-1">
                <li>Peleg AY, et al. "Acinetobacter baumannii: Emergence of a successful pathogen." Clin Microbiol Rev. 2008.</li>
                <li>Antunes LC, et al. "Acinetobacter baumannii: Evolution of a global pathogen." Pathog Dis. 2014.</li>
            </ul>
        </section>

        <!-- Back to Home Link -->
        <div class="mt-6">
            <a href="index.html" class="text-blue-600 hover:underline">&larr; Back to Home</a>
        </div>

    </main>

    <footer class="bg-gray-200 text-center p-4 mt-6">
        &copy; 2025 UTI PathoDB. All rights reserved.
    </footer>

</body>
</html>
